Mast Therapeutics plans to price a public offering of its common stock

Piper Jaffray helps raise funds for phase 3 clinical study of MST-188

By Devika Patel

Knoxville, Tenn., May 28 - Mast Therapeutics, Inc. will price a public sale of common stock with a greenshoe option, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Piper Jaffray is assisting.

Proceeds will be used to fund EPIC, the company's phase 3 clinical study of MST-188 in sickle cell disease, and for working capital and general corporate purposes.

The biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.